{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T09:58:18Z","timestamp":1767175098674,"version":"build-2238731810"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virol J"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12985-017-0879-1","type":"journal-article","created":{"date-parts":[[2017,11,6]],"date-time":"2017-11-06T06:42:23Z","timestamp":1509950543000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Fraction of high-grade cervical intraepithelial lesions attributable to genotypes targeted by a nonavalent HPV vaccine in Galicia, Spain"],"prefix":"10.1186","volume":"14","author":[{"given":"S.","family":"Perez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"I\u00f1arrea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"P\u00e9rez-Tanoira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Gil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"L\u00f3pez-D\u00edez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"Valenzuela","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Porto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Alberte-Lista","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. A.","family":"Peteiro-Cancelo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Treinta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Carballo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. C.","family":"Reboredo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. E.","family":"Alvarez-Arg\u00fcelles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. J.","family":"Purri\u00f1os","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,11,6]]},"reference":[{"key":"879_CR1","doi-asserted-by":"crossref","unstructured":"Van de Velde N, Boily M-C, Drolet M, Franco EL, Mayrand M-H, Kliewer EV, et al. Population-level impact of the bivalent, quadrivalent, and nonavalent human papillomavirus vaccines: a model-based analysis. J Natl Cancer Inst 2012;104:1712\u20131723.","DOI":"10.1093\/jnci\/djs395"},{"key":"879_CR2","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13027-017-0129-6","volume":"12","author":"S Hartwig","year":"2017","unstructured":"Hartwig S, St Guily JL, Dominiak-Felden G, Alemany L, de Sanjos\u00e9 S. Estimation of the overall burden of cancers, precancerous lesions, and genital warts attributable to 9-valent HPV vaccine types in women and men in Europe. Infect Agents Cancer. 2017;12:19.","journal-title":"Infect Agents Cancer"},{"key":"879_CR3","unstructured":"Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. 2013. \nhttp:\/\/globocan.iarc.fr\n\n. Accessed 21 Jul 2014."},{"key":"879_CR4","doi-asserted-by":"crossref","first-page":"e453","DOI":"10.1016\/S2214-109X(16)30099-7","volume":"4","author":"L Bruni","year":"2016","unstructured":"Bruni L, Diaz M, Barrionuevo-Rosas L, Herrero R, Bray F, Bosch FX, et al. Global estimates of human papillomavirus vaccination coverage by region and income level: a pooled analysis. Lancet Glob Health. 2016;4:e453\u201363.","journal-title":"Lancet Glob Health"},{"key":"879_CR5","unstructured":"ECDC. Vaccine Schedule. \nhttp:\/\/vaccine-schedule.ecdc.europa.eu\/Pages\/Scheduler.aspx\n\n. Accessed 20 Apr 2017."},{"key":"879_CR6","unstructured":"Expanded Programme on Immunization (EPI), Department of Immunization, Expanded Programme on ImmVaccines and Biologicals, editors. Guide to Introducing HPV Vaccine into National Immunization Programmes. WHO Document Production Services, Geneva, Switzerland; 2016. \nhttp:\/\/apps.who.int\/iris\/bitstream\/10665\/253123\/1\/9789241549769-eng.pdf?ua=1\n\n. Accessed 20 Apr 2017."},{"key":"879_CR7","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1586\/14760584.2015.964213","volume":"14","author":"SD Isidean","year":"2015","unstructured":"Isidean SD, Tota JE, Gagnon JA, Franco EL. Human papillomavirus vaccines: key factors in planning cost-effective vaccination programs. Expert Rev Vaccines. 2015;14:119\u201333.","journal-title":"Expert Rev Vaccines"},{"key":"879_CR8","doi-asserted-by":"crossref","unstructured":"de Sanjose S, Wheeler CM, Quint WGV, Hunt WC, Joste NE, Alemany L, et al. Age-specific occurrence of HPV16- and HPV18-related cervical cancer. Cancer Epidemiol Biomark Prev 2013;22:1313\u20131318.","DOI":"10.1158\/1055-9965.EPI-13-0053"},{"key":"879_CR9","doi-asserted-by":"crossref","unstructured":"Joste NE, Ronnett BM, Hunt WC, Pearse A, Langsfeld E, Leete T, et al. Human Papillomavirus Genotype-Specific Prevalence Across the Continuum of Cervical Neoplasia and Cancer. Cancer Epidemiol Biomarkers Prev. 2015;24(1):230-40.","DOI":"10.1158\/1055-9965.EPI-14-0775"},{"key":"879_CR10","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1158\/1055-9965.EPI-14-0628","volume":"24","author":"NJ Veldhuijzen","year":"2015","unstructured":"Veldhuijzen NJ, Berkhof J, Gillio-Tos A, Marco LD, Carozzi F, Mistro AD, et al. The age distribution of type-specific high-risk human Papillomavirus incidence in two population-based screening trials. Cancer Epidemiol Biomark Prev. 2015;24:111\u20138.","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"879_CR11","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.eimc.2013.09.011","volume":"32","author":"S P\u00e9rez-Castro","year":"2014","unstructured":"P\u00e9rez-Castro S, Lorenzo-Mah\u00eda Y, I\u00f1arrea Fern\u00e1ndez A, Lamas-Gonz\u00e1lez MJ, Sar\u00e1n-D\u00edez MT, Rubio-Alarc\u00f3n J, et al. Cervical intraepithelial neoplasia grade 2 or worse in Galicia, Spain: HPV 16 prevalence and vaccination impact. Enferm Infecc Microbiol Clin. 2014;32:479\u201385.","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"879_CR12","doi-asserted-by":"crossref","first-page":"3176","DOI":"10.1128\/JCM.42.7.3176-3184.2004","volume":"42","author":"K Sotlar","year":"2004","unstructured":"Sotlar K, Diemer D, Dethleffs A, Hack Y, Stubner A, Vollmer N, et al. Detection and typing of human Papillomavirus by E6 nested multiplex PCR. J Clin Microbiol. 2004;42:3176\u201384.","journal-title":"J Clin Microbiol"},{"issue":"Pt B","key":"879_CR13","first-page":"1","volume":"100","author":"IARC Working Group on the Evaluation of Carcinogenic Risks to Humans","year":"2012","unstructured":"IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Biological agents. Volume 100 B. A review of human carcinogens. IARC Monogr Eval Carcinog Risks Hum. 2012;100(Pt B):1\u2013441.","journal-title":"IARC Monogr Eval Carcinog Risks Hum"},{"key":"879_CR14","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1158\/1055-9965.EPI-14-0410","volume":"23","author":"EA Joura","year":"2014","unstructured":"Joura EA, Ault KA, Bosch FX, Brown D, Cuzick J, Ferris D, et al. Attribution of 12 high-risk human Papillomavirus genotypes to infection and cervical disease. Cancer Epidemiol Biomark Prev. 2014;23:1997\u20132008.","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"879_CR15","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1590\/S1020-49892010000100012","volume":"27","author":"MI Santiago P\u00e9rez","year":"2010","unstructured":"Santiago P\u00e9rez MI, Hervada Vidal X, Naveira Barbeito G, Silva LC, Fari\u00f1as H, V\u00e1zquez E, et al. The Epidat program. Rev Panam Salud Publica. 2010;27:80\u20132.","journal-title":"Rev Panam Salud Publica"},{"key":"879_CR16","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1186\/s12889-015-1779-1","volume":"15","author":"D Riethmuller","year":"2015","unstructured":"Riethmuller D, Jacquard A-C, Lacau St Guily J, Aubin F, Carcopino X, Pradat P, et al. Potential impact of a nonavalent HPV vaccine on the occurrence of HPV-related diseases in France. BMC Public Health. 2015;15:453.","journal-title":"BMC Public Health"},{"key":"879_CR17","doi-asserted-by":"crossref","first-page":"56","DOI":"10.3201\/eid2201.150736","volume":"22","author":"RL Cameron","year":"2016","unstructured":"Cameron RL, Kavanagh K, Pan J, Love J, Cuschieri K, Robertson C, et al. Human Papillomavirus prevalence and herd immunity after introduction of vaccination program, Scotland, 2009-2013. Emerging Infect Dis. 2016;22:56\u201364.","journal-title":"Emerging Infect Dis"},{"key":"879_CR18","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.vaccine.2014.10.045","volume":"33","author":"SL Osborne","year":"2015","unstructured":"Osborne SL, Tabrizi SN, Brotherton JML, Cornall AM, Wark JD, Wrede CD, et al. Assessing genital human papillomavirus genoprevalence in young Australian women following the introduction of a national vaccination program. Vaccine. 2015;33:201\u20138.","journal-title":"Vaccine"},{"key":"879_CR19","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1038\/bjc.2014.479","volume":"111","author":"KGJ Pollock","year":"2014","unstructured":"Pollock KGJ, Kavanagh K, Potts A, Love J, Cuschieri K, Cubie H, et al. Reduction of low- and high-grade cervical abnormalities associated with high uptake of the HPV bivalent vaccine in Scotland. Br J Cancer. 2014;111:1824\u201330.","journal-title":"Br J Cancer"},{"key":"879_CR20","doi-asserted-by":"crossref","first-page":"204","DOI":"10.5694\/mja16.00597","volume":"206","author":"H Ali","year":"2017","unstructured":"Ali H, McManus H, O\u2019Connor CC, Callander D, Kong M, Graham S, et al. Human papillomavirus vaccination and genital warts in young indigenous Australians: national sentinel surveillance data. Med J Aust. 2017;206:204\u20139.","journal-title":"Med J Aust"},{"key":"879_CR21","unstructured":"Ministerio de Sanidad, Servicios Sociales e Igualdad - Profesionales - Vacunas Coberturas de Vacunaci\u00f3n. \nhttps:\/\/www.msssi.gob.es\/profesionales\/saludPublica\/prevPromocion\/vacunaciones\/coberturas.htm\n\n. Accessed 22 Apr 2017."},{"issue":"Suppl 5","key":"879_CR22","doi-asserted-by":"crossref","first-page":"F157","DOI":"10.1016\/j.vaccine.2012.06.091","volume":"30","author":"K Canfell","year":"2012","unstructured":"Canfell K, Chesson H, Kulasingam SL, Berkhof J, Diaz M, Kim JJ. Modeling preventative strategies against human papillomavirus-related disease in developed countries. Vaccine. 2012;30(Suppl 5):F157\u201367.","journal-title":"Vaccine"}],"updated-by":[{"DOI":"10.1186\/s12985-018-0953-3","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2018,3,6]],"date-time":"2018-03-06T00:00:00Z","timestamp":1520294400000}}],"container-title":["Virology Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-017-0879-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,11,6]],"date-time":"2017-11-06T06:42:35Z","timestamp":1509950555000},"score":1,"resource":{"primary":{"URL":"http:\/\/virologyj.biomedcentral.com\/articles\/10.1186\/s12985-017-0879-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,6]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["879"],"URL":"https:\/\/doi.org\/10.1186\/s12985-017-0879-1","relation":{},"ISSN":["1743-422X"],"issn-type":[{"value":"1743-422X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,6]]},"article-number":"214"}}